insights_auto
Hvorfor har 8NE gått opp? 3,28%?
Gå mer i dybdenchevron_right
8NE:FRA
Lisata Therapeutics, Inc.
0,94 €
arrow_upward
+3,28%(+0,030) 1 D
9. okt., 08:05:36 GMT+2 · EUR
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for 8NE …
Åpne
0,94 €
Høy
0,94 €
Lav
0,94 €
Markedsverdi
12,96 mill.
Snittvolum
0,00
Volum
0,00
52 u høy
4,34 €
52 u lav
0,74 €
Antall ansatte
21
Åpne
0,94 €
Høy
0,94 €
Lav
0,94 €
Markedsverdi
12,96 mill.
Snittvolum
0,00
Volum
0,00
52 u høy
4,34 €
52 u lav
0,74 €
Antall ansatte
21
Nyhetssaker
Fra nettkilder og nyhetspartnere
Investing.com
·
for 19 timer siden
Lisata Therapeutics receives patent for certepetide cancer treatment
Stock Titan
·
for 20 timer siden
A new cancer-treatment patent adds market exclusivity into 2043, Lisata says.
Investing.com UK
·
for 1 døgn siden
Form PRE 14A Lisata Therapeutics For: 7 October By Investing.com
Profil
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Om Lisata Therapeutics, Inc.
Administrerende direktør-
Ansatte21
Grunnlagt1980
HovedkontorBasking Ridge, New Jersey, USA
Sektor-
Nettstedlisata.com